Notice of NCI Participation in RFA-ES-18-012, Human Health Exposure Analysis Resource: UnTargeted Exposure Analysis Laboratories (U2C Clinical Trial Not Allowed)

Notice Number: NOT-CA-18-102

Key Dates
Release Date: August 30, 2018

Related Announcements
RFA-ES-18-012

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) will participate, effective immediately, in RFA-ES-18-012, Human Health Exposure Analysis Resource: UnTargeted Exposure Analysis Laboratories (UC2 Clinical Trial Not Allowed). 

The following changes have been made in RFA-ES-18-012 under each of the headings (below) to reflect NCI's participation in this funding opportunity announcement (FOA):

Part 1. Overview Information

Components of Participating Organizations

National Cancer Institute (NCI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.399

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Gary Ellison, Ph.D., M.P.H.
National Cancer Institute
Telephone: 240-276-6783
Email: ellisong@mail.nih.gov

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov

All other aspects of this FOA remain unchanged

Inquiries

Please direct all inquiries to:

Gary Ellison, Ph.D., M.P.H.
National Cancer Institute
Telephone: 240-276-6783
Email: ellisong@mail.nih.gov